by Paul | Feb 7, 2017 | xarelto news
A new research sheds some light on Xarelto’s lack of safety, showing how its side effects are the most dangerous among the new generation of blood thinners. According to the study published in the science journal Gastroenterology, rivaroxaban is the least safe...
by Paul | Jan 6, 2017 | xarelto news
On January 26, the U.S. Judicial Panel on Multidistrict Litigation (JPML) will hear arguments regarding the centralization of several Eliquis lawsuits under a new MDL in Miami, Florida. The drug’s manufacturers Bristol-Myers Squibb and Pfizer Inc. filed a motion...
by Paul | Dec 26, 2016 | xarelto news
A new analysis published by manufacturers Janssen Pharmaceutical and Bayer AG shows that the Novel Oral Anticoagulant (NOAC) Xarelto (rivaroxaban) is safer and less expensive than its competitors in patients affected by cancer. The research that was presented at the...
by Paul | Dec 21, 2016 | xarelto news
ProPublica, an independent non-profit organization, recently published a public report on drugs promotional expenditures, with Xarelto being the top most expensive. The total spending for the infamous blood thinner topped all other medications in the United States in...
by Paul | Dec 6, 2016 | xarelto news
New Xarelto lawsuits keep getting filed every day as the mass tort kept growing as one of the largest in the history of pharmaceutical litigations. One of the latest complaints has been filed on November 14 by a woman from Illinois, and is currently pending in Cook...
by Paul | Oct 19, 2016 | xarelto news
On September 21, 2016, Honorable Judge E. Fallon postponed by 90 days the deadline to file a Xarelto lawsuit in the current multidistrict litigation (MDL Number 2592). The number of new cases increased so steadily over the course of last few months, that the United...
